Brief: Biomx Announces Positive Topline Results From Part 2 Of The Phase 1B/2A Trial Evaluating Bx004
Brief: BiomX Appoints Edward L. Williams to its Board of Directors
Brief: Biomx Announces Completion Of Patient Dosing In Part 2 Of The Phase 1B/2A Study Evaluating Bx004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis
Brief: BiomX Inc Files For Shelf Of Up To 31.8 Mln Shares Of Common Stock By Selling Stockholders
Brief: Biomx Reports First Quarter 2023 Financial Results And Provides Business Update
Brief: BiomX Announces Appointments To Board Of Directors
Brief: Biomx Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: BiomX Announces $7.5 Million Private Placement
Brief: BiomX Announces Positive Results From Part 1 Of The Phase 1B/2A Study Evaluating BX004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis
Brief: Biomx Reports Q3 Loss of $0.23 Per Share
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 0.38010
Brief: Biomx reports Q2 results
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 1.18000
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 1.78000
AMEX RESUMED BIOMX INC UNT
AMEX HALT ADDITIONAL INFORMATION LAST 1.78000